Who is sponsoring NCT03177031?

NCT03177031 is sponsored by Penang Hospital, Malaysia.

What drugs are being tested in NCT03177031?

Interventions in NCT03177031: Stay Safe Link (SSL), Stay Safe (STS).

What condition does NCT03177031 study?

NCT03177031 studies Continuous Ambulatory Peritoneal Dialysis.

Is NCT03177031 still recruiting?

NCT03177031 is currently completed. Last updated 3 October 2019.

Last reviewed 2019-10-03 · How we verify

NCT03177031: CAPD-3

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Performance and Safety Comparison of Stay Safe Link® With Stay Safe® in Patient on CAPD (CAPD-3)

Completed NA Last updated 3 October 2019

What this trial tests

NA trial testing Stay Safe Link (SSL) in Continuous Ambulatory Peritoneal Dialysis in 472 participants. Completed in 26 June 2019.

Timeline

13 June 2017

Primary endpoint
30 April 2019

26 June 2019

Quick facts

Lead sponsor	Penang Hospital, Malaysia
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	other
Enrollment	472
Start date	13 June 2017
Primary completion	30 April 2019
Estimated completion	26 June 2019
Sites	1 location across Malaysia

Drugs / interventions tested

Stay Safe Link (SSL)
Stay Safe (STS)

Conditions studied

Continuous Ambulatory Peritoneal Dialysis — all drugs for Continuous Ambulatory Peritoneal Dialysis →

Sponsor

Penang Hospital, Malaysia

Who can join

18 and older, any sex, with Continuous Ambulatory Peritoneal Dialysis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This post-marketing study is undertaken to compare the clinical effectiveness and safety of two continuous ambulatory peritoneal dialysis produced by Fresenius Medical Care (FMC), i.e. Stay Safe® (STS) that is produced by a plant in Germany and Stay Safe Link® (SSL) that is produced in Malaysia. The study is an open labelled, randomised controlled trial where 434 patients in total will be randomised to either STS or SSL in a 1:1 ratio.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Protocol for a randomised, open-label, parallel group, multicentre controlled study to evaluate the clinical performance and safety of Stay Safe Link compared with Stay Safe in patients with end-stage kidney disease on continuous ambulatory peritoneal dialysis.
Mak WY, Ong LM, Goh BL, Bavanandan S, et al · · 2019 · PMID 30852538 · DOI 10.1136/bmjopen-2018-024589

Verify or expand the search:

Other Penang Hospital, Malaysia trials

Trials by the same sponsor.

NCT06966804 — Comparison of Alpha Blockers (Terazosin and Tamsulosin) in Reducing Ureteral Stent Related Symptoms · Phase 3 · recruiting
NCT04818320 — Favipiravir in High-risk COVID-19 Patients · Phase 3 · completed
NCT04503837 — Personalized Mobile Phone Video Recording to Improve Inhaler Techniques in Asthma Patients. · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03177031 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Penang Hospital, Malaysia
Last refreshed: 3 October 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03177031.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing